Impaired liver function during pregnancy can lead to impaired metabolism and weight gain

Impaired liver function during pregnancy may alter gut bacteria composition and increase the risk of obesity in children, according to results presented at The Society for Endocrinology Annual Conference.

In a rodent of the model of the most common liver disease in pregnancy, the composition of gut bacteria in offspring was altered and liver function impaired, particularly when they were fed a Western-style, high-fat diet.

These findings suggest that children at risk should maintain a healthy diet and that interventions to alter gut bacteria may help reduce childhood obesity rates in the future.

The most common liver disease in pregnancy, intrahepatic cholestasis (ICP), reduces the release of digestive fluid bile from the liver causing bile acids to build up in the blood, impairing liver function, causing severe itching for the mother and increasing risks of stillbirth and preterm birth for the baby.

Previous studies suggest that children of women with ICP are more likely to develop childhood obesity.

Growing evidence suggests the importance of the gut microbiome for good metabolic health and that altered composition can lead to impaired metabolism and weight gain.

No previous studies have investigated the effects of ICP during pregnancy on the gut microbiome of either mothers or their children. Understanding how ICP may lead to obesity in children could help prevent the risk of developing this serious and life-limiting condition.

Dr. Caroline Ovadia from King's College London and colleagues investigated how gut microbiota are affected in the offspring of a mouse model of ICP. The results reported that the offspring had a different gut microbiome composition and liver function, particularly when fed a high-fat diet, which could contribute to impaired metabolism and increase the risk of obesity.

Dr. Ovadia comments:

These findings further suggest that health during pregnancy can have long-term health effects on children, and in this case how gut microbiome alterations may increase the risk of obesity in children on a Western style, high-fat diet."

The results suggest that mice born to mothers with ICP, or other liver diseases, may benefit from maintaining a healthy diet and should avoid fatty foods.

These findings also suggest that targeting microbiome composition with treatment strategies in pregnant women, such as using pre-biotics or pro-biotics, could help prevent the risk of child obesity.

"Understanding changes in the composition of the gut microbiome and their effects may provide new ways of diagnosing patients at particular risk of obesity before it occurs. We could then develop personalized medicine and target appropriate treatments to alter gut bacteria accordingly," Dr. Ovadia adds.

Despite some similarities, mouse and human microbiome composition differ, therefore these findings may not accurately represent outcomes in humans.

However, determining effects on human microbiomes can be difficult as it is harder to obtain samples from the gut, and control diet and environment.

Dr. Ovadia is now examining the composition of stool samples from babies to establish whether they differ from normal if their mother had ICP. She hopes to determine if any treatments are able to alter and normalize the composition of the microbiome, with the aim of reducing the risk of childhood obesity.

Society for Endocrinology